Explanipedia

Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans Open

Uğur Şahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M. Kranz , et al. · 2025

Ebola virus-induced eye sequelae: a murine model for evaluating glycoprotein-targeting therapeutics Open

Hana Lee, Biying Xu, Aaron P. Lewkowicz, Kaliroi Engel, Logan Kelley-Baker , et al. · 2024

Structure of the Inmazeb cocktail and resistance to Ebola virus escape Open

Vamseedhar Rayaprolu, Benjamin O. Fulton, Ashique Rafique, Emilia Arturo, Dewight Williams , et al. · 2023

Rvsv-Ebov-Gp Challenge Models Acute and Chronic Eye Infections with Ebola and Can Be Used to Test Therapeutics that Target the Ebola Glycoprotein Open

Hana Lee, Biying Xu, Aaron P. Lewkowicz, Kaliroi Engel, Logan K. Baker , et al. · 2023

Structure of the Inmazeb cocktail and resistance to escape against Ebola virus Open

Vamseedhar Rayaprolu, Ben Fulton, Ashique Rafique, Emilia Arturo, Dewight Williams , et al. · 2022

Monoclonal antibodies can provide important pre- or post-exposure protection against disease for those not yet vaccinated or in individuals that fail to mount a protective immune response after vaccination. A key concern in use of monother…

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant Open

Xue Wang, Leonid Yurkovetskiy, Kuang Shen, Jeremy Luban, Dudkina Natalya , et al. · 2021

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies Open

Richard Copin, Alina Baum, Elzbieta Wloga, Kristen E. Pascal, Stephanie Giordano , et al. · 2021

Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative …

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans Open

Uğur Şahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M. Kranz , et al. · 2021

REGEN-COV protects against viral escape in preclinical and human studies Open

Richard Copin, Alina Baum, Elzbieta Wloga, Kristen E. Pascal, Stephanie Giordano , et al. · 2021

Summary Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. As rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperati…

Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Open

Uğur Şahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M. Kranz , et al. · 2021

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans Open

Uğur Şahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M. Kranz , et al. · 2020

BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) stabilized in the prefusion conformation, has demonstrated…

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Open

Uğur Şahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M. Kranz , et al. · 2020

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant Open

Leonid Yurkovetskiy, Xue Wang, Kristen E. Pascal, Christopher H. Tomkins-Tinch, Thomas Nyalile , et al. · 2020

Concurrent human antibody and T<sub>H</sub>1 type T-cell responses elicited by a COVID-19 RNA vaccine Open

Uğur Şahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M. Kranz , et al. · 2020

An effective vaccine is needed to halt the spread of the SARS-CoV-2 pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 COVID-19 vaccine trial with …

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant Open

Leonid Yurkovetskiy, Xue Wang, Kristen E. Pascal, Christopher H. Tomkins-Tinch, Thomas Nyalile , et al. · 2020

SUMMARY The SARS-CoV-2 spike (S) protein variant D614G supplanted the ancestral virus worldwide in a matter of months. Here we show that D614G was more infectious than the ancestral form on human lung cells, colon cells, and cells rendered…

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail Open

Johanna K. Hansen, Alina Baum, Kristen E. Pascal, Vincenzo Russo, Stephanie Giordano , et al. · 2020

An antibody cocktail against SARS-CoV-2 There is an urgent focus on antibodies that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike and prevent the virus from entering host cells. Hansen et al. generated…

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies Open

Alina Baum, Benjamin O. Fulton, Elzbieta Wloga, Richard Copin, Kristen E. Pascal , et al. · 2020

An antibody cocktail against SARS-CoV-2 There is an urgent focus on antibodies that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike and prevent the virus from entering host cells. Hansen et al. generated…

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant Open

Leonid Yurkovetskiy, Xue Wang, Kristen E. Pascal, Christopher H. Tomkins-Tinch, Thomas Nyalile , et al. · 2020

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates Open

Kristen E. Pascal, Drew Dudgeon, John C. Trefry, Manu Anantpadma, Yasuteru Sakurai , et al. · 2018

This antibody cocktail provides complementary mechanisms of actions, incorporates novel specificities, and demonstrates high-level postexposure protection from lethal EBOV disease in NHPs. It is now undergoing testing in normal healthy vol…

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection Open

Kristen E. Pascal, Christopher M. Coleman, Alejandro O. Mujica, Vishal Kamat, Ashok Badithe , et al. · 2015

Significance Traditional approaches for development of antibodies are poorly suited to combating the emergence of novel pathogens, as they require multiple steps of laborious optimization and process adaptation for clinical development. He…

Kristen E. Pascal YOU? Author Swipe